Atlas FDA

Restylane Refyne, Restylane Defyne, Restylane Kysse Injectable Gels

FDA premarket approval P140029/S031 · decided 2020-12-04

Approval details

PMA number
P140029
Supplement
S031
Supplement type
135 Review Track For 30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Restylane Refyne, Restylane Defyne, Restylane Kysse Injectable Gels
Generic name
Implant, dermal, for aesthetic use
Applicant
Q-Med AB
Date received
2020-09-14
Decision date
2020-12-04
Days to decision
81 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Uppsala
Statement
Approval of changes to the Line 3 cleanrooms 9:169, 9:170, 9:177 and 9:190 in Facility 2, Building 9 at Q-Med ABs site located at Seminariegatan 21, SE-752 58 Uppsala, Sweden, used for the manufacturing of Restylane Refyne, Restylane Defyne, and Restylane Kysse Injectable Gels.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.